Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state-of-the-art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington Beach, CA. The new laboratory will further increase capacity to support Agendia's strong commercial expansion in the U.S. market, as well as the use of multiple Agendia tests in clinical research. MammaPrint, the company's lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by an increasing number of payers, covering some 100 million lives today.
More...
Linear Mode
